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The ABCs of Hepatitis
HEPATITIS A is caused  
by the Hepatitis A virus (HAV)
HEPATITIS B is caused by the Hepatitis B 
virus (HBV)
HEPATITIS C is caused by the 
Hepatitis C virus (HCV)
U.S. Statistics •  Estimated 2,500 new infections 
in 2014
•  Estimated 19,200 new infections in 2014
•  Estimated 850,000–2.2 million people with chronic 
HBV infection
•  Estimated 30,500 new infections in 2014
•  Estimated 2.7–3.9 million people with 
chronic HCV infection 
Routes of 
Transmission
Ingestion of fecal matter, even in 
microscopic amounts, from: 
•  Close person-to-person contact 
with an infected person
•  Sexual contact with an infected 
person
•  Ingestion of contaminated food 
or drinks
Contact with infectious blood, semen, and other body 
fluids primarily through:
•  Birth to an infected mother
•  Sexual contact with an infected person
•  Sharing of contaminated needles, syringes, or other 
injection drug equipment
•  Needlesticks or other sharp instrument injuries
Contact with blood of an infected person 
primarily through:
•  Sharing of contaminated needles, syringes, 
or other injection drug equipment 
Less commonly through:
•  Sexual contact with an infected person
•  Birth to an infected mother
•  Needlestick or other sharp instrument injuries
Persons at Risk •  Travelers to regions with 
intermediate or high rates  
of Hepatitis A
•  Sex contacts of infected  
persons 
•  Household members or 
caregivers of infected persons
•  Men who have sex with men
•  Users of certain illegal drugs 
(injection and non-injection)
•  Persons with clotting-factor 
disorders
•  Infants born to infected mothers
•  Sex partners of infected persons
•  Persons with multiple sex partners
•  Persons with a sexually transmitted disease (STD)
•  Men who have sex with men
•  Injection drug users 
•  Household contacts of infected persons 
•  Healthcare and public safety workers exposed to 
blood on the job
•  Hemodialysis patients
•  Residents and staff of facilities for developmentally 
disabled persons 
•  Travelers to regions with intermediate or high rates 
of Hepatitis B (HBsAg prevalence of ≥2%)
•  Current or former injection drug users
•  Recipients of clotting factor concentrates 
before 1987
•  Recipients of blood transfusions or donated 
organs before July 1992
•  Long-term hemodialysis patients
•  Persons with known exposures to HCV 
(e.g., healthcare workers after needlesticks, 
recipients of blood or organs from a donor 
who later tested positive for HCV)
•  HIV-infected persons
•  Infants born to infected mothers
Incubation Period 15 to 50 days (average: 28 days) 45 to 160 days (average: 120 days) 14 to 180 days (average: 45 days)
Symptoms of  
Acute Infection
Symptoms of all types of viral hepatitis are similar and can include one or more of the following:  • Fever      • Fatigue        
•  Loss of appetite     • Nausea       • Vomiting      • Abdominal pain      •  Gray-colored bowel movements   •  Joint pain    • Jaundice
Likelihood of 
Symptomatic 
Acute infection
•  < 10% of children < 6 years 
have jaundice
•  40%–50% of children age  
6–14 years have jaundice 
•  70%–80% of persons > 14 
years have jaundice 
•  < 1% of infants < 1 year develop symptoms
•  5%–15% of children age 1-5 years develop symptoms 
•  30%–50% of persons > 5 years develop symptoms 
Note: Symptoms appear in 5%–15% of newly 
infected adults who are immunosuppressed
•  20%–30% of newly infected persons 
develop symptoms of acute disease 
Potential for 
Chronic Infection
None •  Among unimmunized persons, chronic infection 
occurs in >90% of infants, 25%–50% of children 
aged 1–5 years, and 6%–10% of older children  
and adults
•  75%–85% of newly infected persons 
develop chronic infection
•  15%–25% of newly infected persons clear 
the virus
Severity Most persons with acute disease 
recover with no lasting liver 
damage; rarely fatal
•  Most persons with acute disease recover with no 
lasting liver damage; acute illness is rarely fatal
•  15%–25% of chronically infected persons develop 
chronic liver disease, including cirrhosis, liver failure, 
or liver cancer
•  1,800 persons in the United States die with HBV-
related liver disease as documented from death 
certificates
•  Acute illness is uncommon. Those who do 
develop acute illness recover with no lasting liver 
damage.   
•  60%–70% of chronically infected persons 
develop chronic liver disease
•  5%–20% develop cirrhosis over a period of 
20–30 years
•  1%–5% will die from cirrhosis or liver cancer 
•  19,600 deaths in 2014
Continued on next page
CR-012096    8/17
HEPATITIS A HEPATITIS B HEPATITIS C
Serologic Tests 
for Acute 
Infection
•  IgM anti-HAV •  HBsAg in acute and chronic infection
•  IgM anti-HBc is positive in acute infection only
•  No serologic marker for acute infection
Serologic Tests 
for Chronic 
Infection
•  Not applicable—no chronic 
infection
•  HBsAg (and additional markers as needed) •  Screening assay (EIA or CIA) for anti-HCV
•  Verification by an additional, more specific 
assay (e.g., nucleic acid testing (NAT) for 
HCV RNA)
Screening 
Recommendations 
for Chronic 
Infection
•  Not applicable—no chronic 
infection 
Note: Screening for past acute 
infection is generally not 
recommended
Testing is recommended for:
•  All pregnant women 
•  Persons born in regions with intermediate or high 
rates of Hepatitis B (HBsAg prevalence of ≥2%) 
•  U.S.–born persons not vaccinated as infants whose 
parents were born in regions with high rates of 
Hepatitis B (HBsAg prevalence of ≥8%)
•  Infants born to HBsAg-positive mothers
•  Household, needle-sharing, or sex contacts of  
HBsAg-positive persons 
•  Men who have sex with men
•  Injection drug users
•  Patients with elevated liver enzymes (ALT/AST) of 
unknown etiology
•  Hemodialysis patients
•  Persons needing immunosuppressive or cytotoxic therapy
•  HIV-infected persons
•  Donors of blood, plasma, organs, tissues, or semen
Testing is recommended for:
• Persons born from 1945–1965
•  Persons who currently inject drugs or who 
have injected drugs in the past, even if once 
or many years ago
•  Recipients of clotting factor concentrates 
before 1987
•  Recipients of blood transfusions or donated 
organs before July 1992
•  Long-term hemodialysis patients
•  Persons with known exposures to HCV (e.g., 
healthcare workers after needlesticks, 
recipients of blood or organs from a donor 
who later tested positive for HCV)
•  HIV-infected persons
•  Children born to infected mothers (do not 
test before age 18 mos.)
•  Patients with signs or symptoms of liver 
disease (e.g., abnormal liver enzyme tests)
•  Donors of blood, plasma, organs, tissues, 
or semen
Treatment •  No medication available
•  Best addressed through 
supportive treatment
•  Acute: No medication available; best addressed 
through supportive treatment
•  Chronic: Regular monitoring for signs of liver 
disease progression; some patients are treated 
with antiviral drugs
•  Acute: Antivirals and supportive treatment
•  Chronic: Regular monitoring for signs of liver 
disease progression; new direct acting 
antiviral medications offer shorter durations 
of treatment and increased effectiveness, 
including over 90% of patients who  
complete treatment are cured
Vaccination 
Recommendations
Hepatitis A vaccine is 
recommended for: 
•  All children at age 1 year
•  Travelers to regions with 
intermediate or high rates of 
Hepatitis A
•  Men who have sex with men
•  Users of certain illegal drugs 
(injection and non-injection)
•  Persons with clotting-factor 
disorders
•  Persons who work with HAV-
infected primates or with HAV  
in a research laboratory
•  Persons with chronic liver 
disease, including HBV- and 
HCV-infected persons with 
chronic liver disease
•  Family and care givers of recent 
adoptees from countries where 
Hepatitis A is common
•  Anyone else seeking long-term 
protection
Hepatitis B vaccine is recommended for:
•  All infants at birth
•  Older children who have not previously been vaccinated
•  Susceptible sex partners of infected persons
•  Persons with multiple sex partners
•  Persons seeking evaluation or treatment for an STD
•  Men who have sex with men
•  Injection drug users 
•  Susceptible household contacts of infected persons 
•  Healthcare and public safety workers exposed to  
blood on the job
•  Persons with chronic liver disease, including  
HCV-infected persons with chronic liver disease 
•  Persons with HIV infection
•  Persons with end-stage renal disease, including 
predialysis, hemodialysis, peritoneal dialysis, and  
home dialysis patients
•  Residents and staff of facilities for developmentally 
disabled persons 
•  Travelers to regions with intermediate or high rates  
of Hepatitis B (HBsAg prevalence of ≥2%)
•  Unvaccinated adults with diabetes mellitus 19–59 (for 
those aged ≥60 years, at the discretion of clinician)
•  Anyone else seeking long-term protection
There is no Hepatitis C vaccine
Vaccination 
Schedule
2 doses given 6 months apart •  Infants and children: 3 to 4 doses given over a  
6- to 18-month period depending on vaccine type 
and schedule
•  Adults: 3 doses given over a 6-month period (most 
common schedule)
No vaccine available
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